Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 and dacarbazine in metastatic melanoma
NCT01055522Phase 2Terminated
- Sponsor
- Philogen
- Start
- Jun 2008
- Primary completion
- Feb 2013
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of darleukin in melanoma, sponsored by Philogen. Started Jun 2008; status: terminated.
02
Drugs
darleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01055522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01055522.